Your session is about to expire
← Back to Search
Molecular Nanotechnology for Non-Hodgkin's Lymphoma
N/A
Recruiting
Led By Narendranath Epperla, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center B-cell type (GCB) and non-GCB subtypes.
Receiving treatment with curative intent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Study Summary
This trial is testing how well a nanochip can detect genetic markers for diffuse large B-cell lymphoma to help predict how well a person will respond to treatment.
Who is the study for?
This trial is for people with a specific blood cancer called diffuse large B-cell lymphoma (DLBCL) who haven't been treated before. Participants must plan to get all their care at Ohio State University, aim for a cure with treatment, and go through 6 cycles of chemotherapy. They also need to be able to give consent.Check my eligibility
What is being tested?
The study is testing nanochip technology (ILN biochip) to see how well it can monitor the effectiveness of treatments in real-time and detect any return of the disease in patients with DLBCL. Researchers are looking for genetic markers that could predict treatment outcomes.See study design
What are the potential side effects?
Since this trial focuses on monitoring technology rather than direct treatment, there may not be side effects related directly to the ILN biochip itself. However, standard chemotherapy side effects apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a specific type of untreated lymphoma.
Select...
I am undergoing treatment aimed at curing my condition.
Select...
I am scheduled for 6 chemotherapy sessions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Early detection of relapse
Treatment response
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (ILN biochip testing)Experimental Treatment1 Intervention
Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
290,067 Total Patients Enrolled
Narendranath Epperla, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
1 Previous Clinical Trials
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies left for participation in this research?
"According to clinicialtrials.gov, this clinical trial is actively looking for participants. It was first made available on September 26th 2018 and has since been edited as recently as June 2nd 2022."
Answered by AI
How many participants have been accepted into this trial thus far?
"Correct. The details listed on clinicaltrials.gov signify that this study is currently enrolling participants. It was initially published on September 26th 2018, and the most recent update occurred June 2nd 2022. 40 patients are needed to be enrolled from a single site."
Answered by AI
Share this study with friends
Copy Link
Messenger